Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06594913 · ClinicalTrials.gov registry record
Eating Disorders Genetics Initiative 2
A clinical trial of Anorexia Nervosa and Binge-Eating Disorder, sponsored by University of North Carolina, Chapel Hill.
- Recruiting
- Registry status
- 20,000
- Enrollment target
- 5
- Study locations
NCT06594913: Recruiting study of Anorexia Nervosa and Binge-Eating Disorder, sponsored by University of North Carolina, Chapel Hill.
NCT06594913 is a study of Anorexia Nervosa and Binge-Eating Disorder that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 20,000 participants, above the 485-participant average among 43 other Anorexia Nervosa trials with a reported enrollment target (4024% higher). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06594913, a study of Anorexia Nervosa and Binge-Eating Disorder, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.
- RECRUITING
- Registry status
- 20,000 participants
- Enrollment target
- 5
- Study locations
Study Summary
The overarching intention of the Eating Disorder Genetics Initiative 2 (EDGI2) is to increase sample size, diversity, and eating disorder phenotypes. The investigators are enrolling 20,000 new participants with anorexia nervosa (AN), bulimia nervosa (BN), binge-eating disorder (BED), avoidant/restrictive food intake disorder (ARFID), and controls in the US, Mexico, Australia, New Zealand, Sweden, and Denmark. A primary study goal is to enroll at least 30% of participants from underrepresented groups. Participants are asked to complete a series of questionnaires and submit a saliva sample for genotyping. The goal is to better understand eating disorders and how they relate to each other so that better treatments can be developed.
Primary Outcome
The ED100Kv4 is a web-based diagnostic questionnaire, based on the Structured Clinical Interview for Axis 1 Disorders, that applies algorithms to participant responses. The number of participants with each diagnosis (AN, BN, BED, ARFID, and control) will be reported.
Conditions Studied
Interventions
- OTHER Eating disorder diagnosis group
Study Locations (5)
Other
- Comenzar de Nuevo - Monterrey
- Karolinska Institutet - Stockholm
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Queensland
- QIMR Berghofer - Brisbane
Canterbury
- University of Otago - Christchurch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,000 participants |
| Start Date | 2024-10-28 |
| Est. Completion | 2027-08-01 |
What NCT06594913 shows while recruiting
NCT06594913 is an observational study that tracks outcomes without assigning an intervention. Its 20,000 participants enrollment target places it among the larger protocols in the corpus, above the 485-participant average among 43 other Anorexia Nervosa trials with a reported enrollment target (4024% higher).
The record links to 4 conditions, with Anorexia Nervosa appearing as the primary indexed condition, and to 1 intervention - of which Eating disorder diagnosis group is the first listed.
NCT06594913 lists 5 locations in 4 states (Other, North Carolina, Queensland).
Frequently Asked Questions
What is clinical trial NCT06594913 about?
NCT06594913 is a clinical study titled "Eating Disorders Genetics Initiative 2". The overarching intention of the Eating Disorder Genetics Initiative 2 (EDGI2) is to increase sample size, diversity, and eating disorder phenotypes. The investigators are enrolling 20,000 new participants with anorexia nervosa (AN), bulimia nervosa (BN), binge-eating disorder (BED), avoidant/restri...
What is the current status of trial NCT06594913?
This trial is currently recruiting. The enrollment target is 20,000 participants. The study started on 2024-10-28. Estimated completion is 2027-08-01.
What conditions does trial NCT06594913 study?
This clinical trial studies the following conditions: Anorexia Nervosa, Binge-Eating Disorder, Bulimia Nervosa, Avoidant Restrictive Food Intake Disorder.
What interventions are being tested in trial NCT06594913?
The interventions under investigation include: Eating disorder diagnosis group (OTHER).
Who is sponsoring clinical trial NCT06594913?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06594913 being conducted?
This trial has 5 study locations across North Carolina, Queensland, Canterbury. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anorexia Nervosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06594913's enrollment target sits among peer trials
20,000 1st of 43 higher than 43 of 43 other Anorexia Nervosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anorexia Nervosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Diet for Relapse Prevention in Anorexia Nervosa
RECRUITING · NA
-
Facing Eating Disorder Fears for Anorexia Nervosa
RECRUITING · NA
-
Therapeutic Ketogenic Diet in Anorexia Nervosa
RECRUITING · NA
-
Confirming the Effectiveness of Online Guided Self-Help Family-Based Treatment for Adolescent Anorexia Nervosa
RECRUITING · NA
-
Incentive Processing and Learning in Anorexia Nervosa and Bulimia Nervosa
RECRUITING
-
Targeting Social Function in Anxiety and Eating Disorders
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
- NCT00830557 · 20,000 participants
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
- NCT00900471 · 20,000 participants
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
- NCT02735707 · 20,000 participants · Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI